Dr. Samson Gebretnsae has over 10 years of experience in the development of antibody-drug conjugates and sophisticated bioconjugate systems, supported by a robust background in medicinal chemistry.
He has effectively led and implemented bioconjugation technologies, encompassing linker-payload design, scale-up, purification, and analytical characterization across various sectors, including big pharma, biotechnology, and contract development and manufacturing organizations.
His expertise spans from early discovery through preclinical development, demonstrating a proven ability to tackle high-risk conjugation, manufacturability, and Chemistry, Manufacturing, and Controls (CMC) challenges. Dr. Gebretnsae consistently facilitates informed, data-driven decisions in the development process.
Our team is comprised of dedicated specialists committed to advancing bioconjugation innovation through scientific rigor and collaborative partnership.